<DOC>
	<DOCNO>NCT02195518</DOCNO>
	<brief_summary>This phase IV , single-arm , open-label , multi-centre study ass efficacy TDF Chronic hepatitis B ( CHB ) subject following failure multiple Nucleos ( ) ide analogue ( NAs ) . The study enrol 200 CHB subject follow failure multiple NAs . Subjects assess eligibility screen visit , eligible subject return baseline assessment approximately 4 week ( Screening phase ) . In treatment phase enrol subject receive open label TDF dose 300 milligram ( mg ) orally daily . All eligible study subject undergo safety efficacy assessment every 12 week total 14 visit . Tenofovir disoproxil fumarate , oral pro-drug tenofovir ( TFV ) , nucleotide analogue inhibits viral polymerase direct bind incorporation deoxyribonucleic acid ( DNA ) , termination DNA ) chain . TDF highly potent treatment treatment-na√Øve lamivudine ( LAM ) resistant CHB patient . The purpose study evaluate efficacy TDF treatment Chinese CHB patient follow failure multiple NAs . In addition , study also explore relationship baseline factor early HBV DNA suppression long-term virological response . The efficacy TDF multi-drug resistant patient analyse separately . The data generate study could use optimize clinical application TDF provide new evidence management HBV infection follow failure multiple NAs . The result study help Chinese physicians good manage CHB patient follow failure multiple NAs .</brief_summary>
	<brief_title>Tenofovir Disoproxil Fumarate ( TDF ) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B ( CHN ) CHB Multiple Nucleos ( ) Ide Analogues ( NAs ) Failure Points Pts PH4 PMS Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Aged 1865years ( inclusive ) . Male female ; female eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant , include female postmenopausal ) ; , Childbearing potential , negative serum pregnancy test baseline , agree one follow method avoidance pregnancy period study 30 day last dose study medication : Oral contraceptive , either combined progestogen alone , Injectable progestogen , Implants levonorgestrel , Oestrogenic vaginal ring , Percutaneous contraceptive patches. , Intrauterine device ( IUD ) intrauterine system ( IUS ) show expected failure rate le 1 % per year state IUD IUS product label , Has male partner sterilise , Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) vaginal spermicidal agent ( foam/gel/film /cream/suppository ) . The ability understand sign write informed consent prior studyrelated procedure comply requirement study . Positive HBsAg 6 month , antiHBs negative . Serum HBV DNA level &gt; =200 IU/mL study screening ( Use central lab result ) . Experienced multiple NAs treatment failure define HBV DNA great 200 IU/mL least two NAs treatment ( least 6 month continuous treatment NA ( ) , total duration le 12 month ) . In addition , subject judge treat physician adhere previous NA therapy . Agreement participate investigational trial undertake HBV systemic antiviral interferon ( IFN ) regimens participation study . Hepatocellular carcinoma evidence one following : Suspicious focus ultrasound radiological examination , Normal ultrasound history rise serum alphafetoprotein serum alphafetoprotein &gt; 20 nanogram ( ng ) per mL screening . Clinical sign decompensated liver disease baseline . These may include limited : Total serum bilirubin &gt; 1.5 x Upper limit normal range ( ULN ) , International Normalized Ratio &gt; 1.3 , Serum albumin &lt; 32grams per Liter ( g/L ) , History clinical hepatic decompensation ( e.g. , ascites , variceal bleeding , encephalopathy ) . Creatinine clearance le 70 milliliter per minute ( mL/min ) . Alanine aminotransferase &gt; 10 time ULN screen history acute exacerbation lead transient decompensation . Haemoglobin &lt; 8 gram per deciliter ( g/dL ) , absolute neutrophil count &lt; 1.0 x 10^9 per Liter , platelets &lt; 75 x 10^9 per Liter . Documented coinfection hepatitis A ( HAV ) , hepatitis C ( HCV ) , hepatitis delta virus ( HDV ) , hepatitis E virus ( HEV ) Human immunodeficiency virus ( HIV ) . For HCV coinfection , subject antiHCV positive HCV RNA undetectable consider eligible enrolment . Evidence active liver disease due autoimmune hepatitis ( antinuclear antibody titre &gt; 1:160 ) Any serious active medical psychiatric illness hepatitis B , opinion Investigator , would interfere subject treatment , assessment compliance protocol . This would include uncontrolled clinically significant renal , cardiac , pulmonary , vascular , neurogenic , digestive , metabolic ( diabetes , thyroid disorder , adrenal disease ) , immunodeficiency disorder , pathological fracture cancer . Active alcohol drug abuse history alcohol drug abuse consider Investigator sufficient hinder compliance treatment , participation study interpretation result . A female breastfeeding plan breast . Use immunosuppressive therapy , immunomodulatory therapy [ include Pegylated interferon ( PEGIFN ) shortacting interferon thymosin alpha ] , systemic cytotoxic agent within previous 6 month prior screen . Planned liver transplantation previous liver transplantation . Receipt TDF within 6 month prior screen . Therapy nephrotoxic drug ( e.g. , aminoglycosides , amphotercin B , vancomycin , cidofovir , foscarnet , cisplatinum , pentamidine etc . ) competitor renal excretion ( e.g. , probenecid ) within 2 month prior study screen expectation subject receive course study . History hypersensitivity nucleoside and/or nucleotide analogues and/or component study medication . Inability comply study requirement determine study Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Tenofovir disoproxil fumarate</keyword>
	<keyword>Failure multiple NAs treatment</keyword>
</DOC>